Amgen (AMGN) Q3 2024 Earnings Call Transcript
My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...
Yahoo Finance21d
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA ...
Investing21d
Amgen's UPLIZNA shows promise in myasthenia gravis trial
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has revealed positive results from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a treatment for adults with generalized myasthenia gravis (gMG).
GlobalData on MSN5d
Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
Amgen Inc (AMGN) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Pipeline ...
Amgen Inc (AMGN) reports a 23% revenue increase, driven by strong product sales and promising developments in its innovative ...
Investing21d
Amgen's UPLIZNA shows promise in myasthenia gravis trial
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has revealed positive results from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a treatment for adults with generalized myasthenia gravis (gMG).